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Summary In vitro and in vivo clinical and experimental data have suggested that leukotrienes play
a key role in inflammatory reactions of the skin. Antileukotriene drugs, i.e. leukotriene
receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory
drugs that have shown clinical efficacy in the management of asthma. We searched the
MedLine database and carried out a manual search on journals specializing in allergy
and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might
be effective in chronic urticaria associated with aspirin or food additive hypersensitivity
or with autoreactivity to intradermal serum injection when taken with an
antihistamine but not in moderate chronic idiopathic urticaria. Evidence for the
effectiveness of zafirlukast and the 5-lipoxygenase inhibitor, zileuton, in chronic
urticaria is mainly anecdotal. In addition, there is anecdotal evidence of effectiveness
of antileukotrienes in primary cold urticaria, delayed pressure urticaria and
dermographism. No evidence exists for other physical urticarias, including
cholinergic, solar and aquagenic urticarias, vibratory angio-oedema, and exercise-
induced anaphylaxis.
Introduction
Urticaria is a common disorder of the skin, affecting
between one in four and one in six people, sometimes
throughout their lives. Individual lesions usually last
for minutes or a few hours and rarely for up to 48 h or
occasionally even longer, when severe. Urticarial epi-
sodes of up to 6 weeks’ duration are classified as acute,
whereas those lasting longer are considered chronic.
Furthermore, chronic urticaria (CU) may persist for at
least 1 year in more than 50% and for more than
20 years in 20% of those affected.1–3
Pathogenesis of urticaria
The common element of urticaria appears to be the hive
or weal, i.e. the ‘final pathway’ involving dermal mast
cells. This pathway is activated by various trigger
factors through immunological or nonimmunological
mechanisms and the result is the release of preformed
(e.g. histamine) and newly synthesized mediators (e.g.
arachidonic acid metabolites), with potent effects on the
microvasculature. Activated mast cells may also release
other substances, such as chemotactic factors, cyto-
kines, enzymes and neuropeptides, which recruit and
activate various inflammatory cells, such as lympho-
cytes and polymorphonuclear cells (e.g. neutrophils and
eosinophils).4 Various investigators have found in-
creased levels of inflammatory mediators and ⁄ or factors
in the different types of urticaria (Table 1).1–3 More
recently, CU has also been proposed to be an auto-
immune disorder, as approximately 30–50% of these
patients present a positive autologous serum skin test
(ASST), with circulating IgG antibodies directed against
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the a-subunit of the high-affinity IgE receptor (FcRI) or
against IgE, which activate basophils and mast cells to
release histamine.4
In our recent study, we demonstrated that both
aspirin (ASA) and food additives determine a significant
increase in urinary leukotriene 4 (LTE4) levels, after oral
specific challenge in patients with CU and hypersensi-
tivity to ASA or food additives. The urinary LTE4 levels
were compared between patients with CU and hyper-
sensitivity to ASA or food additives, patients with CU but
tolerating both ASA and food additives, and healthy
subjects. No difference was found at baseline between
the three groups. After a specific challenge with ASA
and food additives, the urinary excretion levels of LTE4
were significantly higher in patients affected by CU and
hypersensitivity to ASA or food additives than in
patients with CU but without hypersensitivity to ASA
or food additives and in healthy subjects.5
Therapy for urticaria
For most patients, first-line therapy is with H1 antihis-
tamines. Nonsedating antihistamines, such as cetirizine,
levocetirizine, loratadine, desloratadine and fexofena-
dine, alleviate pruritus and decrease the incidence of
weals in patients with mild CU. If nonsedating H1
blockers are only partially effective, the therapeutic
options are: increase the dose of nonsedating H1
blockers or combine these with a sedative H1 antihis-
tamines (hydroxyzine or diphenhydramine or chlorphe-
niramine), taken at night, or add an H2 antihistamine
blocker. The response to the latter option is often
modest.6,7
Oral corticosteroids almost always control urticaria
and are undoubtedly the most versatile and useful
second-line therapy. However, the incidence of side-
effects is substantial if the dose, the duration of use, or
both, are too great.8 Other second-line therapies include
sulphasalazine9 and thyroxine.10
While third-line, immunosuppressive therapies for
severe CU are now accepted practice, there is still the
problem of knowing which patients have autoimmune
urticaria and are therefore most likely to respond, even
if there is some evidence for the therapeutic effect of
immunosuppression therapy in patients without auto-
immune urticaria.11
Urticaria treatment with antileukotrienes
We searched the MedLine database and carried out a
manual search on journals specializing in allergy and
dermatology for the use of antileukotriene drugs in
urticaria. Even though treatment with antileukotrienes
in urticaria has not been recommended by manufac-
turers of the drugs, we found numerous anecdotal and
open-series reports and some placebo-controlled studies
on the treatment of urticaria with cysteinyl-leukotriene
antagonists (Table 2). The studies were evaluated using
the Scottish Intercollegiate Guidelines Network (SIGN)
coding.12
Anecdotal series and open studies
Anecdotal studies suggested therapeutic effects for
antileukotrienes in the treatment of urticaria exacerba-
tions induced by ASA13 and other nonsteroidal anti-
inflammatory drugs (NSAIDs) in patients with CU,14
chronic autoimmune urticaria,15 acquired cold urti-
caria,16,17 delayed-pressure urticaria (DPU),18 and
intractable CU.19 A single negative study reported a
pranlukast-evoked urticaria in patients affected by ASA-
induced urticaria;20 however, this molecule is not
marketed in Europe.
Other open studies, with more patients, suggested a
beneficial effect for antileukotrienes in the treatment of
DPU,21 steroid-dependent urticaria22,23 chronic idio-
pathic urticaria,24,25 and dermographism.24 Patients
with allergic urticaria showed less benefit.24
Controlled studies
A double-blind, placebo-controlled study demonstrated
a better therapeutic effect of montelukast vs. cetirizine
and placebo in patients with ASA and ⁄ or food additive-
induced urticaria.26
Perez et al. demonstrated that in individuals with
histories of recurrent episodes of urticaria and ⁄ or angio-
oedema after the administration of different NSAIDs,
pretreatment with montelukast before a single-blind
Table 1 Type of urticaria, mediators and factors.
Type of urticaria Mediators and factors
Dermographism Histamine, tryptase, ECP, NP
Pressure urticaria Histamine, LTs, ECP, MBP, IL-3, IL-6, TNF-a
Cold urticaria Histamine, LTs, kinins, PAF, PGD2, ECP, IL-3,
IL-6, TNF-a, ECF, NCF
Solar or cholinergic
urticaria
Histamine, tryptase, ECP, MBP, ECF
Chronic urticaria Histamine, LTs, ECP, MBP, IL-3, TNF-a
ECP, eosinophil cationic protein; NP, neuropeptides; LTs, leukot-
rienes; MBP, major basic protein; IL, interleukin; TNF-a, tumour
necrosis factor-alpha; PAF, platelet-activating factor; PGD2, pros-
taglandin D2; ECF, eosinophil cationic factor; NCF, neutrophil
chemotactic factor.
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oral challenge with NSAIDs, completely or partially
prevented the reaction in most of those patients.27
Nettis et al. treated patients affected by chronic
idiopathic urticaria with montelukast or fexofenadine.
They demonstrated that montelukast had a better
therapeutic effects compared with fexofenadine. The
majority of the patients presented a positive ASST and,
after therapy with montelukast, were unreactive to
autologous serum.28
In a double-blind, placebo-controlled trial comparing
cetirizine plus zafirlukast vs. cetirizine plus placebo in
patients affected by CU refractory to H1-antagonist
monotherapy, Bagenstose et al. demonstrated that only
patients with autoreactive (positive ASST) CU might
benefit from the addition of the leukotriene receptor
antagonist zafirlukast to their treatment regimen.29
A randomized, single-blind, placebo-controlled, cross-
over study with montelukast vs. placebo, using a
nonsedating H1-antihistamine when needed, demon-
strated that montelukast might be an effective and safe
therapeutic agent in the treatment of patients with
refractory chronic idiopathic urticaria, including pa-
tients with intolerance to NSAIDs and positivity to
ASST.30
Reimers et al. in a double-blind, placebo-controlled,
crossover study, treated with zafirlukast a heterogene-
ous population of patients with CU. In comparison with
placebo, treatment with zafirlukast resulted in no
significant positive effect for any of the efficacy meas-
ures, but it may be relevant that a high proportion of
patients had dermographism.31
Nettis et al. reported on another randomized, double-
blind, placebo-controlled study conducted on patients
with a diagnosis of mild CU, randomized to receive
once daily: (i) oral desloratadine plus placebo; (ii)
desloratadine plus montelukast; or (iii) oral placebo
alone. In this study, the combination of desloratadine
plus montelukast was effective in the treatment of
CU.32
We have treated 160 patients affected by chronic
idiopathic urticaria with montelukast alone or in
combination with a nonsedating antihistamine (des-
loratadine), or only with nonsedating antihistamine, or
with matched placebo. In this study. we evaluated only
patients affected by moderate chronic idiopathic urti-
caria. This is an important difference compared with
some of the previous reports, in which patients were
selected without precise characteristics.22,23,31 In
patients with moderate chronic idiopathic urticaria,
the role of leukotrienes is probably rather insignifi-
cant.5,29 In this study, montelukast alone was less
effective than the combination with nonsedating
antihistamine and appeared not to be useful in
controlling the symptoms of urticaria compared with
nonsedating antihistamine alone. Therefore, the expec-
ted synergistic interaction between antileukotrienes
and antihistamines was not confirmed in chronic
idiopathic urticaria.33
Conclusions
Research into the cause of urticaria is important for
disease management. Clinically, this is important for the
choice of therapy in these patients, considering that
particular subgroups of patients affected by CU with
ASA or food additive hypersensitivity, or IgG antibodies
directed against the a-subunit of the high-affinity IgE
receptor or IgE,25 do not all respond to H1 antihista-
mines.17,22
Considering the results of the open series and of the
few available controlled studies on the use of anti-
leukotrienes in the treatment of CU, it is now possible to
affirm that, in patients with no known cause of urticaria
without ASA or food additive hypersensitivity, and
those without positive ASST, the use of leukotriene
receptor antagonists in combined therapy with a H1
antihistamine does not produce a substantial benefit for
urticaria symptoms compared with antihistamine
administered as monotherapy.29,33,34 Combined ther-
apy may be useful in control of urticaria induced by
ASA or food additives urticaria or in patients with a
positive ASST, or those affected by acquired cold
urticaria and DPU.
Studies on the use of antileukotrienes in the treat-
ment of chronic urticaria show different results in
patients with ASA and ⁄ or NSAIDs,13,14,26,27,30 and ⁄ or
in patients with food additive hypersensitivity,26 and in
patients with positive ASST.14,15,23,28–30 However, in
many studies, challenge with ASA15,19,22–25,28,29,31,32
and ⁄ or ASST13,19,22,24–27,31,32 have not been reported
or performed. Finally, many patients were affected by
physical urticaria.16–18,21
The most common adverse effects observed in
randomized controlled clinical trials on asthmatic
patients treated with antileukotrienes were headache,
pharyngitis, cough, abdominal pain and dyspepsia.
However, only two case reports also described gener-
alized urticaria induced by antileukotriene treatment
in ASA-induced urticaria21 and in asthmatic pa-
tients.35 Thus, the results of the controlled studies
and clinical experience indicate that these agents
are generally safe and well-tolerated, with an inci-
dence of adverse effects generally comparable with
placebo.26–33
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Learning points
• In vitro and in vivo clinical and experimental
data have suggested that leukotrienes play a key
role in inflammatory reactions of the skin.
• Leukotriene receptor antagonists and synthesis
inhibitors are a new class of anti-inflammatory
drugs that have shown clinical efficacy in the
management of asthma.
• The MedLine database was searched and a
manual search on journals specializing in allergy
and dermatology was carried out for the use of
antileukotriene drugs in urticaria.
• The studies were evaluated using the SIGN
(Scottish Intercollegiate Guidelines Network) cod-
ing.
• Montelukast may be effective in chronic urti-
caria associated with hypersensitivity to aspirin or
food additives or with autoreactivity to intradermal
serum injection when taken with an antihista-
mine, but not in moderate chronic idiopathic
urticaria.
• Evidence for effectiveness of zafirlukast and the
5-lipoxygenase inhibitor, zileuton, in chronic
urticaria is mainly anecdotal.
• In addition, there is anecdotal evidence of
effectiveness of antileukotrienes in primary cold
urticaria, delayed pressure urticaria and dermo-
graphism. No evidence exists for other physical
urticarias, including cholinergic, solar and aqua-
genic urticaria, vibratory angio-oedema, and exer-
cise-induced anaphylaxis.
• The results of the controlled studies and clinical
experience indicate that these agents are generally
safe and well-tolerated, with an incidence of
adverse effects generally comparable with placebo.
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